Search
Nimesulide
go.drugbank.com/drugs/DB04743ApprovedInvestigationalWithdrawnDue to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.
Categories: Topical Products for Joint and Muscular Pain, Cytochrome P-450 SubstratesAdriforant
go.drugbank.com/drugs/DB15027InvestigationalAdriforant is under investigation in clinical trial NCT00992342 (A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers).
Synonyms: PF-03893787Zalifrelimab
go.drugbank.com/drugs/DB15632InvestigationalZalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).
PF-5212372
go.drugbank.com/drugs/DB19212InvestigationalPF-5212372 is under investigation in clinical trial NCT02795832 (A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis).
Lauric acid
go.drugbank.com/drugs/DB03017ApprovedLauric acid is an inexpensive, non-toxic and safe to handle compound often used in laboratory investigations of melting-point depression. … Lauric acid is a solid at room temperature but melts easily in boiling water, so liquid lauric acid can be treated with various solutes and used to determine their molecular masses.
Netilmicin
go.drugbank.com/drugs/DB00955ApprovedNetilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseAcoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigationalAcoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. … [A264768] Although they share a mechanism of action, acoramidis is more selective for TTR and is a more potent stabilizer when compared to tafamidis.
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsPlant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine
go.drugbank.com/drugs/DB16757ApprovedCovifenz COVID-19 vaccine (plant-based virus-like particles (VLP), recombinant, adjuvanted) is a plant-based vaccine developed in partnership by Medicago and GlaxoSmithKline which is approved in Canada for
Tovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigational[A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersClesrovimab
go.drugbank.com/drugs/DB18877ApprovedInvestigationalto provide passive immunization against RSV infection as an alternative means of protection. … [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233]